Trial · NCT00928954
Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus
NCT00928954, Not applicable, Completed, Case Western Reserve University; results first posted 2016-07-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus. Trials, record NCT00928954. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00928954
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus
- NCT number
- NCT00928954
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 10 participants, actual
- Lead sponsor
- Case Western Reserve University
- Conditions
- Nystagmus
- Interventions
- gabapentin, memantine
- First posted
- 2009-06-26
- Last updated
- 2016-07-29
- Results first posted
- 2016-07-29
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing | After 2 weeks of therapy, for both drugs | |
| Primary | Percent Change in Median Eye Speed | After 2 weeks of therapy, for both drugs | Median eye speed during attempted visual fixation by each eye |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing | After 2 weeks of therapy, for both drugs | logMAR | NUMBER | |
| PRIMARY | Percent Change in Median Eye Speed | After 2 weeks of therapy, for both drugs | Percent change | NUMBER |
Source ClinicalTrials.gov
Results by group80
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing | Gabapentin | Participant 1, Right Eye | 0 | logMAR | |
| Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing | Memantine | Participant 1, Right Eye | 0.1 | logMAR | |
| Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing | Gabapentin | Participant 1, Left Eye | 0.2 | logMAR | |
| Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing | Memantine | Participant 1, Left Eye | 0.2 | logMAR | |
| Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing | Gabapentin | Participant 2, Right Eye | 0.1 | logMAR | |
| Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing | Memantine | Participant 2, Right Eye | 0.2 | logMAR | |
| Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing | Gabapentin | Participant 2, Left Eye | 0.2 | logMAR | |
| Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing | Memantine | Participant 2, Left Eye | 0 | logMAR | |
| Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing | Gabapentin | Participant 3, RIght Eye | -0.1 | logMAR | |
| Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing | Memantine | Participant 3, RIght Eye | -0.2 | logMAR |
1 to 10 of 80Source ClinicalTrials.gov
See all 80 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Gabapentin First and Then Memantine | 4 | |
| Overall Study | STARTED | Memantine First, Then Gabapentin | 6 | |
| Overall Study | COMPLETED | Gabapentin First and Then Memantine | 4 | |
| Overall Study | COMPLETED | Memantine First, Then Gabapentin | 6 | |
| Overall Study | NOT COMPLETED | Gabapentin First and Then Memantine | 0 | |
| Overall Study | NOT COMPLETED | Memantine First, Then Gabapentin | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Gabapentin | ||
| Total, all-cause mortality | Memantine | ||
| Total, other adverse events | Gabapentin | 0 | 10 |
| Total, other adverse events | Memantine | 0 | 10 |
| Total, serious adverse events | Gabapentin | 0 | 10 |
| Total, serious adverse events | Memantine | 0 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Gabapentin vs Memantine: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00928954
GET https://conductscience.org/api/trials/v1/NCT00928954/results?page=2